E.I.D Parry’s Microalgae Facility Successfully Completes U.S. FDA Inspection, Paves Way for New Products

ORLANDO, FL (8 May 2017)Parry Nutraceuticals, a division of E.I.D Parry, a global leader in microalgae-based nutraceuticals, announced today that its Organic Spirulina and Chlorella cultivation and processing facility, located in Oonaiyur, Pudukottai District, Tamil Nadu, India has formally received an Establishment Inspection Report (EIR). This is pursuant to the successful inspection of the facility carried out by FDA as provided by the provisions of 21 CFR 20.64(d)(3) in July 2016 and follow up satisfactory response submitted by the Company.

“We are very proud of the result achieved during the FDA inspection. This success is testament to our ongoing commitment towards our quality systems,” said Muthu Murugappan, Business Head.

Based in Chennai, India, Parry Nutraceuticals is a division of EID Parry India Ltd, and part of the Murugappa Group, with more than 30 years of experience in cultivation and processing of microalgae-based nutraceuticals. This includes Organic Spirulina, Organic Chlorella, Haematococcus pluvialis and other Phytochemicals. Parry Nutraceuticals is globally recognized, with its products sold under all major brands across the continents, for its superior product quality and safety.

According to Murugappan, Parry Nutraceuticals is dedicated to providing a wider array of value-added products from microalgae in the coming years, to meet the latest consumer demands. “Our new product strategy is one of value addition from our existing ‘greens’ stable, coupled with an entry into newer Algal and Phytochemical verticals. In this regard, some of the products that we will bring to the market in 2017 include Organic Chlorella, Spirulina granules, CO2 extracted Lutein and Algal Beta-glucan, to name a few. These, along with Vegan Plant Proteins, Chlorophyll, Phycocyanin and Algae Omega 3s, are some of the exciting new areas of focus for the company, with very active development.”

E.I.D Parry (India) Ltd. (NSE: EIDPARRY) — E.I.D Parry (India) Limited is a public company headquartered in Chennai, South India that has been in business for more than 225 years.

Valensa International, based in Orlando, Florida, is a subsidiary of EID Parry which specializes in development of condition-specific nutraceuticals, backed by clinical science and intellectual property protection. Products developed through Parry Nutraceuticals are available in North America through Valensa International. In 2014, EID Parry acquired Alimtec SA based in Chile for cultivation of Heamtococcus Pluvialis for extraction of Astaxanthin, a powerful antioxidant, which is Valensa’s flagship product, manufactured in Florida and marketed under its registered trademark brand Zanthin® Natural Astaxanthin.

Additional Valensa & Parry brands include: FlexPro MD® and FlexPro ES® joint health formulations, Go Easy®, Immunum™, EyePro MD®, Pur-Blue® SpiruZan® (Spirulina with Astaxanthin), Prostate 360™, Cran-Gyn® & FemCool® Women’s Health Formulas, Organic USPlus® Saw Palmetto Extract, Tresalbio® Stabilized Chia Seed Oil, Verilla™ Perilla Oil, Gingerol®, Parry Organic Spirulina, and Parry Tomato Lycopene Complex.